Remdesivir, mAb114, REGN-EB3, and ZMapp partially rescue nonhuman primates infected with a low passage Kikwit variant of Ebola virus

• Published in: Nature communications Vol. 16; no. 1; pp. 3824 - 13
• Main Authors: Prasad, Abhishek N., Woolsey, Courtney, Borisevich, Viktoriya, Agans, Krystle N., Deer, Daniel J., Geisbert, Joan B., Harrison, Mack B., Dobias, Natalie S., Fenton, Karla A., Cross, Robert W., Geisbert, Thomas W.
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 23.04.2025; Nature Publishing Group; Nature Portfolio
• Subjects: 13; 13/51; 631/250/2152/2153/1291; 631/326/22/1295; 631/326/596/2042; 64; Adenosine Monophosphate - analogs & derivatives; Adenosine Monophosphate - pharmacology; Adenosine Monophosphate - therapeutic use; Alanine - analogs & derivatives; Alanine - pharmacology; Alanine - therapeutic use; Animals; Antibodies, Monoclonal - pharmacology; Antibodies, Monoclonal - therapeutic use; Antibodies, Monoclonal, Humanized - pharmacology; Antibodies, Monoclonal, Humanized - therapeutic use; Antiviral Agents - pharmacology; Antiviral Agents - therapeutic use; Disease Models, Animal; Ebola virus; Ebolavirus; Ebolavirus - drug effects; Ebolavirus - genetics; Ebolavirus - immunology; Effectiveness; Female; Health services; Hemorrhagic Fever, Ebola - drug therapy; Hemorrhagic Fever, Ebola - mortality; Hemorrhagic Fever, Ebola - virology; Humanities and Social Sciences; Humans; Macaca mulatta; Male; Monoclonal antibodies; multidisciplinary; Patients; Primates; Science; Science (multidisciplinary); Survival; Viral diseases; Viruses

In 2018, a clinical trial of four investigational therapies for Ebola virus disease (EVD), known as the PALM trial, was conducted in the Democratic Republic of Congo. All patients received either the antiviral remdesivir (RDV) or a monoclonal antibody product: ZMapp, mAb114 (Ebanga), or REGN-EB3 (In...